在這工作中，我們考慮KP腫瘤模型的動態系統。
首先，非負解是個別奠定無界性和有界性的解的充分條件，
    然後我們呈現了在使用及不使用免疫療法的無腫瘤平衡解。
透過線性系統的局部分析，證明了無腫瘤平衡解的局部穩定性。
    此外，也研究全域的動態結果。
接下來，我們找到正平衡解的存在性的充分條件，
    不幸的是，還是有可能有其它正平衡解。
最後，我們有一些探討生物意義和數值模擬的結果。

In this work, we consider the dynamics of KP tumor model [12]. First, the non-negativity of solutions are showed and sufficient conditions to guarantee the unboundedness and boundedness of solution are established, respectively. Then we present the explicit form of tumor-free equilibrium with or without treatment. By applying local analysis to the linearized system, local stability of the tumor free equilibrium are verified. Moreover, a global dynamical result is also investigated. Next, we find the sufficient condition of the existence of positive equilibria. Unfortunately, there maybe have other positive equilibria. Finally, some biological implications and numerical simulations are presented in the last section.

Contents
1. Induction........................................1
2. Prelimary........................................4
3. Existence and Local Stability of Equilibria......9
4. Immunotherapy...................................11
5. Numerical Simulations and Discussion............12

List of Figures
1. The graphs of both side of equation(3.2)........11
2. Numerical simulation of solution of (1.1).......14
3. Numerical simulation of solution of (1.1).......14

List of tables
1. Parameter Values : units are in 1/day except 
     for g1, g2, g3, and b whose units are volume..13

Reference
[1] E. Bianconi, A. Piovesan, F. Facchin, A. Beraudi, R. Casadei, F. Frabetti, L. Vitale, M. C. Pelleri, S. Tassani, F. Piva, S. Perez-Amodio, P. Strippoli, and S. Canaider. An estimation of the number of cells in the human body. Annals of Human Biology, 40(6):463–471, 2013.

[2] T. Boon and P. van der Bruggen. Human tumor antigens recognized by T lymphocytes. The Journal of experimental medicine, 183(3):725–729, 1996.

[3] B. D. Curti, A. C. Ochoa, W. J. Urba, W. G. Alvord, W. C. Kopp, G. Powers, C. Hawk, S. P. Creekmore, B. L. Gause, J. E. Janik, J. T. Holmlund, P. Kremers,
R. G. Fenton, L. Miller, M. Sznol, J. W. I. Smith, W. H. Sharfman, and D. L. Longo. Influence of Interleukin-2 Regimens on Circulating Populations of Lymphocytes After Adoptive Transfer of Anti-CD3-Stimulated T Cells:
Results from a Phase I Trial in Cancer Patients. Journal of Immunotherapy, 19(4):296, 1996.

[4] R. J. De Boer, P. Hogeweg, H. F. Dullens, R. A. De Weger, and W. Den Otter. Macrophage T lymphocyte interactions in the anti-tumor immune response: a mathematical model. Journal of immunology (Baltimore, Md. : 1950), 134(4):2748–2758, 1985.

[5] K. E. de Visser, A. Eichten, and L. M. Coussens. Paradoxical roles of the immune system during cancer development. Nature Reviews Cancer, 6(1): 24–37, 2006.

[6] C. DeLisi and A. Rescigno. Immune surveillance and neoplasia. I. A minimal mathematical model. Bull. Math. Biology, 39(2):201–221, 1977.

[7] B. L. Gause, M. Sznol, W. C. Kopp, J. E. Janik, J. W. S. 2nd, R. G. Steis, W. J. Urba, W. Sharfman, R. G. Fenton, S. P. Creekmore, J. Holmlund, K. C. Conlon, L. A. VanderMolen, and D. L. Longo. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. Journal of Clinical Oncology, 14(8):2234–2241, 1996.

[8] M. Gerloni and M. Zanetti. CD4 T cells in tumor immunity. Springer seminars in immunopathology, 27(1):37–48, 2005.

[9] I. Hara, H. Hotta, N. Sato, H. Eto, S. Arakawa, and S. Kamidono. Rejection of Mouse Renal Cell Carcinoma Elicited by Local Secretion of Interleukin-2. Japanese Journal of Cancer Research, 87(7):724–729, 1996.

[10] R. Kaempfer, L. Gerez, H. Farbstein, L. Madar, O. Hirschman, R. Nussinovich, and A. Shapiro. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. Journal
of Clinical Oncology, 14(6):1778–1786, 1996.

[11] U. Keilholz, C. Scheibenbogen, E. Stoelben, H. D. Saeger, and W. Hunstein.Immunotherapy of metastatic melanoma with interferon-  and interleukin-2: Pattern of progression in responders and patients with stable disease with or without resection of residual lesions. European Journal of Cancer, 30(7):955–958, 1994.

[12] D. Kirschner and J. C. Panetta. Modeling immunotherapy of the tumor – immune interaction. Journal of Mathematical Biology, 37(3):235–252, 1998.

[13] V. A. Kuznetsov, I. A. Makalkin, M. A. Taylor, and A. S. Perelson. Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. Bulletin of Mathematical Biology, 56(2):295–321, 1994.

[14] A. J. Lumsden, J. P. Codde, P. H. Van Der Meide, and B. N. Gray. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferongamma. Anticancer research, 16(3A):1145–1154, 1996.

[15] F. M. Marincola, D. E. White, A. P. Wise, and S. A. Rosenberg. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. Journal of Clinical Oncology, 13(5):1110–1122, 1995.

[16] L. Markus. Asymptotically autonomous differential systems. In Contributions to the theory of nonlinear oscillations, vol. 3, pages 17–29. Princeton University Press, Princeton, N. J., 1956.

[17] H. Rabinowich, M. Banks, T. E. Reichert, T. F. Logan, J. M. Kirkwood, and T. L. Whiteside. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clinical Cancer Research, 2(8):1263–1274, 1996.

[18] S. A. Rosenberg. Progress in human tumour immunology and immunotherapy. Nature, 411(6835):380–384, 2001. [19] S. A. Rosenberg and M. T. Lotze. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annual review of immunology, 4(1): 681–709, 1986.

[20] S. A. Rosenberg, J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell
Cancer Using High-Dose Bolus Interleukin 2. JAMA, 271(12):907–913, 1994.

[21] M. Rosenstein, S. E. Ettinghausen, and S. A. Rosenberg. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. Journal of immunology, 137(5):1735–1742, 1986.

[22] D. J. Schwartzentruber. In vitro predictors of clinical response in patients receiving interleukin-2-based immunotherapy. Current opinion in oncology, 5(6):1055, 1993.

[23] A. Sohrabi, J. Sandoz, J. S. Spratt, and H. C. Polk. Recurrence of Breast Cancer: Obesity, Tumor Size, and Axillary Lymph Node Metastases. JAMA, 244(3):264–265, 1980.

[24] K. E. Starkov and L. N. Coria. Global dynamics of the Kirschner–Panetta model for the tumor immunotherapy. Nonlinear Analysis: Real World Applications, 14(3):1425–1433, 2013.

[25] L. Zamai, C. Ponti, P. Mirandola, G. Gobbi, S. Papa, L. Galeotti, L. Cocco, and M. Vitale. NK cells and cancer. Journal of immunology, 178(7):4011–4016, 2007.